NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Get Started
$25.02 -0.16 (-0.64 %)
(As of 05/24/2018 04:12 AM ET)
Previous Close$25.02
Today's Range$24.95 - $25.88
52-Week Range$8.01 - $29.90
Volume299,283 shs
Average Volume540,204 shs
Market Capitalization$845.60 million
P/E Ratio-10.13
Dividend YieldN/A
Beta0.78

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:COLL
CUSIPN/A
Webwww.collegiumpharma.com
Phone781-713-3699

Debt

Debt-to-Equity Ratio3.91
Current Ratio0.83
Quick Ratio0.80

Price-To-Earnings

Trailing P/E Ratio-10.13
Forward P/E Ratio-20.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$28.48 million
Price / Sales29.03
Cash FlowN/A
Price / CashN/A
Book Value$2.75 per share
Price / Book9.10

Profitability

EPS (Most Recent Fiscal Year)($2.47)
Net Income$-74,860,000.00
Net Margins-78.22%
Return on Equity-72.87%
Return on Assets-26.11%

Miscellaneous

Employees250
Outstanding Shares33,040,000

Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its quarterly earnings data on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.02. The specialty pharmaceutical company earned $63.70 million during the quarter, compared to analyst estimates of $51.92 million. Collegium Pharmaceutical had a negative net margin of 78.22% and a negative return on equity of 72.87%. Collegium Pharmaceutical's revenue for the quarter was up 2835.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.79) earnings per share. View Collegium Pharmaceutical's Earnings History.

What price target have analysts set for COLL?

6 equities research analysts have issued 12-month target prices for Collegium Pharmaceutical's shares. Their forecasts range from $26.00 to $35.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $31.80 in the next twelve months. View Analyst Ratings for Collegium Pharmaceutical.

Who are some of Collegium Pharmaceutical's key competitors?

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:
  • Mr. Michael T. Heffernan, Founder, Chairman, Pres & CEO (Age 54)
  • Mr. Paul J. Brannelly, Exec. VP & CFO (Age 45)
  • Mr. Joseph J. Ciaffoni, Exec. VP & COO (Age 47)
  • Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 43)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 34)

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Has Collegium Pharmaceutical been receiving favorable news coverage?

News stories about COLL stock have been trending positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Collegium Pharmaceutical earned a daily sentiment score of 0.33 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 46.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.99%), Rock Springs Capital Management LP (5.81%), Franklin Resources Inc. (4.45%), Massachusetts Financial Services Co. MA (1.25%), Prudential Financial Inc. (1.05%) and Summit Trail Advisors LLC (1.01%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, John A Fallon, Longitude Capital Partners, Ll, Michael Thomas Heffernan and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.

Which major investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Prudential Financial Inc., Wells Fargo & Company MN, Granite Investment Partners LLC, Franklin Resources Inc., Millennium Management LLC, Cortina Asset Management LLC and Massachusetts Financial Services Co. MA. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Longitude Capital Partners, Ll and Michael Thomas Heffernan. View Insider Buying and Selling for Collegium Pharmaceutical.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Osterweis Capital Management Inc., Russell Investments Group Ltd., Tygh Capital Management Inc., Timpani Capital Management LLC, Fisher Asset Management LLC, UBS Group AG and JPMorgan Chase & Co.. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $25.02.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $845.60 million and generates $28.48 million in revenue each year. The specialty pharmaceutical company earns $-74,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Collegium Pharmaceutical employs 250 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 780 DEDHAM STREET SUITE 800, CANTON MA, 02021. The specialty pharmaceutical company can be reached via phone at 781-713-3699.


MarketBeat Community Rating for Collegium Pharmaceutical (COLL)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Collegium Pharmaceutical (NASDAQ:COLL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Collegium Pharmaceutical in the last 12 months. Their average twelve-month price target is $31.80, suggesting that the stock has a possible upside of 27.10%. The high price target for COLL is $35.00 and the low price target for COLL is $26.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.80$31.80$29.40$20.00
Price Target Upside: 27.10% upside33.84% upside35.05% upside18.91% upside

Collegium Pharmaceutical (NASDAQ:COLL) Consensus Price Target History

Price Target History for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2018William BlairReiterated RatingOutperformHighView Rating Details
3/8/2018HC WainwrightBoost Price TargetBuy ➝ Buy$21.00 ➝ $33.00HighView Rating Details
2/12/2018Jefferies GroupBoost Price TargetBuy$32.00LowView Rating Details
2/12/2018Piper Jaffray CompaniesSet Price TargetBuy$33.00HighView Rating Details
2/7/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$28.00 ➝ $35.00LowView Rating Details
2/6/2018Janney Montgomery ScottSet Price TargetBuy ➝ Buy$21.00 ➝ $26.00LowView Rating Details
9/13/2016GabelliInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Collegium Pharmaceutical (NASDAQ:COLL) Earnings History and Estimates Chart

Earnings by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.77)
2019 EPS Consensus Estimate: $0.46
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.73)($0.23)($0.48)
Q2 20183($0.31)($0.12)($0.22)
Q3 20183($0.18)($0.05)($0.09)
Q4 20183($0.05)$0.15$0.02
Q1 20191($0.13)($0.13)($0.13)
Q2 20191$0.13$0.13$0.13
Q3 20191$0.21$0.21$0.21
Q4 20191$0.25$0.25$0.25

Collegium Pharmaceutical (NASDAQ COLL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.55)($0.57)$51.92 million$63.70 millionViewN/AView Earnings Details
3/7/2018Q4 2017($0.56)($0.54)$9.88 million$10.79 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.73)($0.45)$5.31 million$11.95 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.81)($0.72)$4.07 million$3.56 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.9760)($0.79)$3.55 million$2.17 millionViewN/AView Earnings Details
3/9/2017Q4 2016($1.07)($1.02)$1.79 million$1.30 millionViewListenView Earnings Details
11/10/2016Q3 2016($1.09)($1.13)$1.00 million$0.41 millionViewListenView Earnings Details
8/10/2016Q2($0.7580)($1.05)$0.16 millionViewListenView Earnings Details
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details
8/12/2015Q215($0.26)($0.45)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Collegium Pharmaceutical (NASDAQ:COLL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Collegium Pharmaceutical (NASDAQ COLL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.87%
Institutional Ownership Percentage: 92.51%
Insider Trading History for Collegium Pharmaceutical (NASDAQ:COLL)
Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ COLL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2018Michael Thomas HeffernanChairmanSell44,400$26.00$1,154,400.00545,893View SEC Filing  
1/23/2018Michael Thomas HeffernanChairmanSell20,000$25.01$500,200.00535,395View SEC Filing  
1/19/2018Michael Thomas HeffernanChairmanSell20,000$22.50$450,000.00538,987View SEC Filing  
1/10/2018Alison B FlemingInsiderSell6,928$19.07$132,116.9632,651View SEC Filing  
12/8/2017Longitude Capital Partners, LlMajor ShareholderSell1,000,000$17.34$17,340,000.00View SEC Filing  
11/21/2017Alison B FlemingInsiderSell4,601$17.25$79,367.2528,513View SEC Filing  
11/17/2017Alison B FlemingCTOSell4,029$17.00$68,493.0028,513View SEC Filing  
11/15/2017Michael Thomas HeffernanCEOSell50,000$15.53$776,500.00558,987View SEC Filing  
5/12/2017Paul BrannellyInsiderBuy10,000$9.18$91,800.00110,227View SEC Filing  
8/12/2016John A FallonDirectorBuy2,375$10.59$25,151.252,375View SEC Filing  
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Collegium Pharmaceutical (NASDAQ COLL) News Headlines

Source:
DateHeadline
Brokerages Expect Collegium Pharmaceutical (COLL) Will Announce Quarterly Sales of $72.39 Million Brokerages Expect Collegium Pharmaceutical (COLL) Will Announce Quarterly Sales of $72.39 Million
www.americanbankingnews.com - May 16 at 4:28 AM
Collegium Pharmaceutical (COLL) Downgraded by Zacks Investment Research to "Hold"Collegium Pharmaceutical (COLL) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 15 at 8:15 PM
BidaskClub Upgrades Collegium Pharmaceutical (COLL) to "Buy"BidaskClub Upgrades Collegium Pharmaceutical (COLL) to "Buy"
www.americanbankingnews.com - May 15 at 1:31 PM
Jefferies Group Analysts Boost Earnings Estimates for Collegium Pharmaceutical (COLL)Jefferies Group Analysts Boost Earnings Estimates for Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - May 14 at 5:05 AM
Analysts Expect Collegium Pharmaceutical (COLL) to Post -$0.19 EPS Analysts Expect Collegium Pharmaceutical (COLL) to Post -$0.19 EPS
www.americanbankingnews.com - May 14 at 3:27 AM
Q2 2018 EPS Estimates for Collegium Pharmaceutical (COLL) Reduced by AnalystQ2 2018 EPS Estimates for Collegium Pharmaceutical (COLL) Reduced by Analyst
www.americanbankingnews.com - May 14 at 2:37 AM
FY2021 Earnings Forecast for Collegium Pharmaceutical (COLL) Issued By Piper JaffrayFY2021 Earnings Forecast for Collegium Pharmaceutical (COLL) Issued By Piper Jaffray
www.americanbankingnews.com - May 11 at 11:47 AM
Depomed Announces First-Quarter 2018 Financial ResultsDepomed Announces First-Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 8:41 AM
Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product LaunchKala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch
www.bizjournals.com - May 10 at 8:41 AM
Collegium Pharmaceuticals (COLL) CEO Michael Heffernan on Q1 2018 Results - Earnings Call TranscriptCollegium Pharmaceutical's (COLL) CEO Michael Heffernan on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:41 AM
Edited Transcript of COLL earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of COLL earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:41 AM
Collegium Pharmaceutical (COLL) Releases Earnings Results, Misses Expectations By $0.02 EPSCollegium Pharmaceutical (COLL) Releases Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 10 at 12:14 AM
Collegium Pharmaceutical misses by $0.08, beats on revenueCollegium Pharmaceutical misses by $0.08, beats on revenue
seekingalpha.com - May 9 at 5:17 PM
Collegium Pharmaceutical: 1Q Earnings SnapshotCollegium Pharmaceutical: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:17 PM
Collegium Reports First Quarter Financial Results and Provides Corporate UpdateCollegium Reports First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 5:17 PM
Where Collegium Pharmaceutical Inc (NASDAQ:COLL) Stands In Earnings Growth Against Its IndustryWhere Collegium Pharmaceutical Inc (NASDAQ:COLL) Stands In Earnings Growth Against Its Industry
finance.yahoo.com - May 9 at 5:17 PM
Collegium Pharmaceutical (COLL) Downgraded to D at TheStreetCollegium Pharmaceutical (COLL) Downgraded to D at TheStreet
www.americanbankingnews.com - May 9 at 3:12 PM
Collegium Pharmaceutical (COLL) Receives Average Recommendation of "Buy" from BrokeragesCollegium Pharmaceutical (COLL) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 3 at 5:32 AM
Collegium to Present at the Deutsche Bank Health Care ConferenceCollegium to Present at the Deutsche Bank Health Care Conference
finance.yahoo.com - May 2 at 5:14 PM
Collegium Pharmaceutical (COLL) Scheduled to Post Quarterly Earnings on WednesdayCollegium Pharmaceutical (COLL) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 7:08 AM
Collegium Pharmaceutical (COLL) Expected to Announce Quarterly Sales of $49.64 MillionCollegium Pharmaceutical (COLL) Expected to Announce Quarterly Sales of $49.64 Million
www.americanbankingnews.com - April 28 at 2:48 AM
Collegium Pharmaceutical (COLL) Stock Rating Lowered by BidaskClubCollegium Pharmaceutical (COLL) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 27 at 12:18 PM
Analysts Anticipate Collegium Pharmaceutical (COLL) to Post -$0.68 Earnings Per Share Analysts Anticipate Collegium Pharmaceutical (COLL) to Post -$0.68 Earnings Per Share
www.americanbankingnews.com - April 26 at 3:10 PM
Analysts Issue Forecasts for Collegium Pharmaceuticals FY2020 Earnings (COLL)Analysts Issue Forecasts for Collegium Pharmaceutical's FY2020 Earnings (COLL)
www.americanbankingnews.com - April 25 at 9:38 AM
Michael Thomas Heffernan Sells 44,400 Shares of Collegium Pharmaceutical (COLL) StockMichael Thomas Heffernan Sells 44,400 Shares of Collegium Pharmaceutical (COLL) Stock
www.americanbankingnews.com - April 23 at 7:10 PM
Investor Expectations to Drive Momentum within WESCO International, Microchip ...Investor Expectations to Drive Momentum within WESCO International, Microchip ...
globenewswire.com - April 23 at 9:06 AM
Collegium Pharmaceutical (COLL) Upgraded at BidaskClubCollegium Pharmaceutical (COLL) Upgraded at BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
Collegium Pharmaceutical (COLL) to Post Q1 2018 Earnings of ($0.73) Per Share, William Blair ForecastsCollegium Pharmaceutical (COLL) to Post Q1 2018 Earnings of ($0.73) Per Share, William Blair Forecasts
www.americanbankingnews.com - April 18 at 7:58 AM
William Blair Comments on Collegium Pharmaceuticals FY2019 Earnings (COLL)William Blair Comments on Collegium Pharmaceutical's FY2019 Earnings (COLL)
www.americanbankingnews.com - April 17 at 7:05 AM
Collegium Pharmaceutical (COLL) Upgraded by Zacks Investment Research to "Buy"Collegium Pharmaceutical (COLL) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 16 at 8:40 PM
Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 16 at 9:16 AM
Brokerages Anticipate Collegium Pharmaceutical (COLL) Will Announce Quarterly Sales of $49.73 Million Brokerages Anticipate Collegium Pharmaceutical (COLL) Will Announce Quarterly Sales of $49.73 Million
www.americanbankingnews.com - April 11 at 2:23 AM
-$0.69 EPS Expected for Collegium Pharmaceutical (COLL) This Quarter-$0.69 EPS Expected for Collegium Pharmaceutical (COLL) This Quarter
www.americanbankingnews.com - April 9 at 5:24 PM
Collegium Pharmaceutical (COLL) Given Consensus Recommendation of "Buy" by BrokeragesCollegium Pharmaceutical (COLL) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 8 at 5:11 AM
Collegium Pharmaceutical (COLL) Downgraded by BidaskClub to "Hold"Collegium Pharmaceutical (COLL) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 5 at 10:33 AM
Collegium to Present at the H.C. Wainwright Global Life Sciences ConferenceCollegium to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 4 at 4:36 PM
Collegium Pharmaceutical (COLL) Upgraded by ValuEngine to "Buy"Collegium Pharmaceutical (COLL) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - April 3 at 5:52 PM
HC Wainwright Reaffirms Buy Rating for Collegium Pharmaceutical (COLL)HC Wainwright Reaffirms Buy Rating for Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - April 1 at 10:34 AM
Collegium Pharmaceutical (COLL) Downgraded by BidaskClub to BuyCollegium Pharmaceutical (COLL) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - March 30 at 9:27 AM
BidaskClub Upgrades Collegium Pharmaceutical (COLL) to BuyBidaskClub Upgrades Collegium Pharmaceutical (COLL) to Buy
www.americanbankingnews.com - March 28 at 11:21 AM
Piper Jaffray Analysts Give Collegium Pharmaceutical (COLL) a $33.00 Price TargetPiper Jaffray Analysts Give Collegium Pharmaceutical (COLL) a $33.00 Price Target
www.americanbankingnews.com - March 26 at 9:18 PM
$49.73 Million in Sales Expected for Collegium Pharmaceutical Inc (COLL) This Quarter$49.73 Million in Sales Expected for Collegium Pharmaceutical Inc (COLL) This Quarter
www.americanbankingnews.com - March 25 at 2:54 AM
Commit To Buy Collegium Pharmaceuticals At $17.50, Earn 14.9% Annualized Using Options - NasdaqCommit To Buy Collegium Pharmaceuticals At $17.50, Earn 14.9% Annualized Using Options - Nasdaq
www.nasdaq.com - March 24 at 8:27 AM
Notice to Convene Annual General Meeting 2018Notice to Convene Annual General Meeting 2018
finance.yahoo.com - March 23 at 8:33 AM
Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel - GlobeNewswire (press release)Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel - GlobeNewswire (press release)
globenewswire.com - March 20 at 8:12 AM
Collegium Announces the Appointment of Shirley Kuhlmann as General CounselCollegium Announces the Appointment of Shirley Kuhlmann as General Counsel
finance.yahoo.com - March 19 at 9:08 AM
Collegium Pharmaceutical Inc (COLL) Given Average Recommendation of "Buy" by BrokeragesCollegium Pharmaceutical Inc (COLL) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 14 at 5:36 AM
Contrasting Collegium Pharmaceutical (COLL) & Corcept Therapeutics (CORT)Contrasting Collegium Pharmaceutical (COLL) & Corcept Therapeutics (CORT)
www.americanbankingnews.com - March 14 at 1:26 AM
Brokers Issue Forecasts for Collegium Pharmaceutical Incs FY2019 Earnings (COLL)Brokers Issue Forecasts for Collegium Pharmaceutical Inc's FY2019 Earnings (COLL)
www.americanbankingnews.com - March 12 at 8:51 AM
William Blair Analysts Increase Earnings Estimates for Collegium Pharmaceutical Inc (COLL)William Blair Analysts Increase Earnings Estimates for Collegium Pharmaceutical Inc (COLL)
www.americanbankingnews.com - March 12 at 2:32 AM

SEC Filings

Collegium Pharmaceutical (NASDAQ:COLL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Collegium Pharmaceutical (NASDAQ:COLL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Collegium Pharmaceutical (NASDAQ COLL) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.